Kriya Therapeutics announce promising pre-clinical results for KRIYA-825, a single gene therapy delivered via suprachoroidal injection for the treatment of geographic atrophy (GA).
KRIYA-825 is an adeno-associated virus (AAV)-based gene therapy that expresses a complement CR2-CR1 fusion protein. This therapeutic design aims to inhibit the activity of both complement C3 and C5, two critical drivers of inflammatory damage in GA.
Existing treatments for GA require monthly or bimonthly intravitreal injections, which Kriya aims to eliminate with just a single injection of gene therapy.
Read more here:
